Cargando…

Correction: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study

[Image: see text]

Detalles Bibliográficos
Autores principales:	McCue, Maggie, Sarkey, Sara, Eramo, Anna, François, Clement, Parikh, Sagar V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178841/ https://www.ncbi.nlm.nih.gov/pubmed/35676662 http://dx.doi.org/10.1186/s12888-022-03975-3

Ejemplares similares

Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study
por: McCue, Maggie, et al.
Publicado: (2021)

Correction to: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study
por: McCue, Maggie, et al.
Publicado: (2022)

Adapting the Goal Attainment Approach for Major Depressive Disorder
por: McCue, Maggie, et al.
Publicado: (2019)

Patient attitudes toward and goals for MDD treatment: a survey study
por: McNaughton, Emily C, et al.
Publicado: (2019)

Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot Study
por: McCue, Maggie, et al.
Publicado: (2022)

Design of a real-world, prospective, longitudinal, observational study to compare vortioxetine with other standard of care antidepressant treatments in patients with major depressive disorder: a PatientsLikeMe survey
por: Raveendran, Subhara, et al.
Publicado: (2023)

Reduced Specificity of Personal Goals and Explanations for Goal Attainment in Major Depression
por: Dickson, Joanne M., et al.
Publicado: (2013)

Vortioxetine Improved Depressive State In Parkinson’s Disease
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
por: Cao, Bing, et al.
Publicado: (2019)

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

Design and Implementation of a Digitally Enabled Care Pathway to Improve Management of Depression in a Large Health Care System: Protocol for the Implementation of a Patient Care Platform
por: Khatib, Rasha, et al.
Publicado: (2023)

Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2022)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez, Enric, et al.
Publicado: (2014)

Effects of Vortioxetine on Sleep Architecture of Adolescents with Major Depressive Disorder
por: Mlyncekova, Zuzana, et al.
Publicado: (2023)

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder
por: Florea, Ioana, et al.
Publicado: (2017)

Major depression with musical obsession treated with vortioxetine: a case report
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine
por: Ye, Xiaolin, et al.
Publicado: (2021)

Emotional blunting and cognitive profile in elderly depressed patients in treatment with vortioxetine
por: Franza, F., et al.
Publicado: (2021)

5.13 The Experience of Children and Adolescents With ADHD and Their Caregivers During the COVID-19 Pandemic: The UNCOVER Study
por: Thorley, Eileen Mack, et al.
Publicado: (2021)

Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study
por: Wang, Gang, et al.
Publicado: (2022)

A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders
por: Findling, Robert L., et al.
Publicado: (2018)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Attaining Goals Through Partnerships
por: Ramirez, Julio J.
Publicado: (2003)

New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
por: Katona, Cornelius L, et al.
Publicado: (2014)

Depression and Cerebrovascular Disease: Could Vortioxetine Represent a Valid Treatment Option?
por: Carta, Mauro Giovanni, et al.
Publicado: (2015)

Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature
por: Kelliny, Marc, et al.
Publicado: (2015)

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research
por: Bennabi, Djamila, et al.
Publicado: (2019)

Case Report: Vortioxetine in the Treatment of Depressive Symptoms in Patients With Epilepsy—Case Series
por: Siwek, Marcin, et al.
Publicado: (2022)

Effect of vortioxetine on proinflammatory cytokine levels in patients with heart failure and comorbid depression
por: Sikora, A., et al.
Publicado: (2021)

Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults
por: Zhang, Xinyan, et al.
Publicado: (2022)

Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial
por: Mills, Natalie T, et al.
Publicado: (2020)

A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)
por: Ng, Chong Guan, et al.
Publicado: (2023)

Usefulness of vortioxetine noted in depression secondary to hypoxic brain injury and residual cognitive deficits
por: Ahsan, Syeda Maheen, et al.
Publicado: (2020)

Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression
por: Segura-Garcia, Cristina, et al.
Publicado: (2021)

A Case of Major Depression with Burning Mouth Syndrome and Tinnitus Successfully Treated with Vortioxetine
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects
por: Papalexi, Eugenia, et al.
Publicado: (2022)

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults
por: McIntyre, Roger S., et al.
Publicado: (2014)

A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment
por: Basurte-Villamor, Ignacio, et al.
Publicado: (2022)

Vortioxetine Treatment for Depression in Alzheimer’s Disease: A Randomized, Double-blind, Placebo-controlled Study
por: Jeong, Hye Won, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d7rmruhjp84ubkrh1p4q3dteql